Ascendis Pharma A/S (NASDAQ:ASND – Get Rating) hit a new 52-week low during mid-day trading on Thursday after Wedbush lowered their price target on the stock from $128.00 to $117.00. Wedbush currently has an outperform rating on the stock. Ascendis Pharma A/S traded as low as $103.65 and last traded at $105.90, with a volume […]
Ascendis Pharma A/S (NASDAQ:ASND – Get Rating) announced its quarterly earnings data on Wednesday. The biotechnology company reported ($1.87) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($2.30) by $0.43, Fidelity Earnings reports. Ascendis Pharma A/S had a negative return on equity of 50.72% and a negative net margin of 12,211.21%. […]
Squarepoint Ops LLC cut its holdings in Ascendis Pharma A/S (NASDAQ:ASND – Get Rating) by 39.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,908 shares of the biotechnology company’s stock after selling 2,569 shares during the period. Squarepoint Ops LLC’s holdings […]
Ascendis Pharma A/S (NASDAQ:ASND – Get Rating) posted its quarterly earnings data on Wednesday. The biotechnology company reported ($1.87) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($2.30) by $0.43, Fidelity Earnings reports. Ascendis Pharma A/S had a negative return on equity of 50.72% and a negative net margin of 12,211.21%. […]
Ascendis Pharma A/S (NASDAQ:ASND – Get Rating) had its price objective lowered by Credit Suisse Group from $196.00 to $188.00 in a report issued on Thursday, The Fly reports. The brokerage currently has an outperform rating on the biotechnology company’s stock. Other equities analysts have also issued reports about the stock. SVB Leerink lifted their […]